Sino Biopharm’s invoX to restructure, likely cutting about 60 roles

On­col­o­gy and res­pi­ra­to­ry drug de­vel­op­er in­voX Phar­ma is fine-tun­ing its pipeline and ex­pects to cut about one-third of its em­ploy­ees, the com­pa­ny con­firmed to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.